Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 2/20 | 0.55 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.54 |
| ▸ | HTR2A | P28223 | 3/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1539105 | 0.85 | TAAR1 (0.65) | GABBR2GABBR1TAAR1HTR2ACHRNB2 | |
| SCHEMBL3031215 | 0.85 | TAAR1 (0.43) | GABBR2GABBR1TAAR1HTR2AHRH1 | |
| Hydrochloric Acid SCHEMBL10676327 | 0.82 | TAAR1 (0.62) | GABBR2GABBR1TAAR1HTR2ACHRNB2 | |
| SCHEMBL7517934 | 0.76 | TRPA1 (0.42) | GABBR2GABBR1TAAR1HTR2ADPP4 | |
| SCHEMBL9137323 | 0.76 | HRH1 (0.62) | GABBR2GABBR1TAAR1HTR2ACHRNB2 | |
| SCHEMBL9126415 | 0.76 | HRH1 (0.39) | GABBR2GABBR1TAAR1HTR2AHRH1 | |
| SCHEMBL7666405 | 0.76 | GABBR2 (0.55) | GABBR2GABBR1TAAR1HTR2ACHRNB2 | |
| SCHEMBL429746 | 0.76 | GABBR2 (0.55) | GABBR2GABBR1TAAR1HTR2ACHRNB2 | |
| SCHEMBL429745 | 0.76 | GABBR2 (0.55) | GABBR2GABBR1TAAR1HTR2ACHRNB2 | |
| SCHEMBL7277441 | 0.76 | TAAR1 (0.37) | GABBR2GABBR1TAAR1HTR2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174509-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | ARIVA MED GMBH (AT) | 2023-06-08 | — | — | US | claimed |
| EP-4135683-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | Nabriva Therapeutics GMBH (AT) | 2023-02-22 | — | — | EP | claimed |
| CN-115413238-A | Therapeutic use of pleuromutilin compounds | 纳布里瓦治疗有限责任公司 | 2022-11-29 | — | — | CN | claimed |
| WO-2021209596-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2021-10-21 | — | — | WO | claimed |
| EP-3096751-B1 | 12-EPI-PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2021-01-06 | — | — | EP | claimed |
| CN-105916499-B | 12-epi-pleuromutilins | 纳布里瓦治疗股份公司 | 2020-02-18 | — | — | CN | claimed |
| US-9701628-B2 | 12-epi pleuromutilins | NABRIVA THERAPEUTICS AG (AT) | 2017-07-11 | — | — | US | claimed |
| EP-3096751-A1 | 12-EPI-PLEUROMUTILINS | Nabriva Therapeutics AG (AT) | 2016-11-30 | — | — | EP | claimed |
| US-20160332963-A1 | 12-EPI PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2016-11-17 | — | — | US | claimed |
| CN-105916499-A | 12-epi-pleuromutilins | 纳布里瓦治疗股份公司 | 2016-08-31 | — | — | CN | claimed |
| WO-2015110481-A1 | 12-EPI-PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2015-07-30 | — | — | WO | claimed |
| CN-104211695-A | New use of group of carbamyl phenylsulfonyl compounds | INST MED BIOTECHNOLOGY CAMS | 2014-12-17 | — | — | CN | claimed |
| CN-1353689-A | Novel hydroxamic acid derivatives | DAIICHI PREC KAGAKU (JP) | 2002-06-12 | — | — | CN | claimed |
| EP-1179529-A1 | NOVEL HYDROXAMIC ACID DERIVATIVES | Daiichi Fine Chemical Co., Ltd. (JP) | 2002-02-13 | — | — | EP | claimed |
| CN-1284060-A | Novel metalloprotease inhibitors | FUJI YAKUHIN KOGYO KK (JP) | 2001-02-14 | — | — | CN | claimed |
| EP-1038864-A1 | NOVEL METALLOPROTEINASE INHIBITORS | FUJI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 2000-09-27 | — | — | EP | claimed |
| US-20240208989-A1 | NOVEL 12-EPI-MUTILIN COMPOUNDS AND USES THEREOF | ARIVA MED GMBH (AT) | 2024-06-27 | — | — | US | disclosed |
| EP-4323366-A1 | NOVEL 12-EPI-MUTILIN COMPOUNDS AND USES THEREOF | Nabriva Therapeutics GMBH (AT) | 2024-02-21 | — | — | EP | disclosed |
| EP-1038864-A1 | NOVEL METALLOPROTEINASE INHIBITORS | FUJI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 2000-09-27 | — | — | EP | disclosed |
| CN-1216986-A | Isoxazole derivatives | SANKYO CO (JP) | 1999-05-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208989-A1 | NOVEL 12-EPI-MUTILIN COMPOUNDS AND USES THEREOF | MTNR1A, MSH6, MSH2 | GABBR2 3743/4885GABBR1 3584/4885TAAR1 2460/4885 |
| US-20160332963-A1 | 12-EPI PLEUROMUTILINS | MLN, TCF12, PLEC | GABBR2 1961/4885GABBR1 1694/4885TAAR1 1333/4885 |
| US-20230174509-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | MLN, PLEC, PELP1 | GABBR2 2557/4885GABBR1 2147/4885TAAR1 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.